Added text to state that U.S. transplant and cancer registries show that posttransplant lymphoproliferative disease (PTLD) accounts for about 3% of all pediatric NHL diagnoses; and that 65% of PTLDs are diffuse large B-cell lymphoma histology, and 9% are Burkitt histology (cited Yanik et al. as reference 9).
Revised text to state that other studies found that a positive minimal residual disease (MRD) at the end of induction was not prognostic, possibly because of the low number of relapses in patients with disease detected in blood or marrow at diagnosis (cited Shiramizu et al. as reference 23).
Revised text to state that studies using the dose-adjusted (DA)–EPOCH protocol (etoposide, prednisone, vincristine, and doxorubicin) with rituximab have reported an event-free survival higher than 80% (cited Giulino-Roth et al. as reference 41).
Added text about the results of a Japanese Pediatric Leukemia/Lymphoma Study Group trial that treated 28 patients with R-ICE (ifosfamide, carboplatin, and etoposide plus rituximab) (cited Osumi et al. as reference 35). Also added text about the results of a retrospective review of patients with relapsed disease who were treated on the LMB-89, LMB-96, and LMB-2001 trials.
Added text about the results of a multicenter, retrospective study of 38 pediatric patients and 118 adult patients treated with the DA-EPOCH-R regimen (cited Giulino-Roth et al. as reference 61).
Added text to state that for patients who achieved a complete remission, 5-year progression-free survival was 69% for those who received a transplant and 48% for those who did not receive a transplant; the difference was not statistically significant (cited Pro et al. as reference 37).
Added text to state that U.S. transplant and cancer registries show that PTLD accounts for about 3% of all pediatric NHL diagnoses; and that 65% of PTLDs are diffuse large B-cell lymphoma histology, and 9% are Burkitt histology (cited Yanik et al. as reference 14).
ver historia personal en: www.cerasale.com.ar [dado de baja por la Cancillería Argentina por temas políticos, propio de la censura que rige en nuestro medio]//
weblog.maimonides.edu/farmacia/archives/UM_Informe_Autoevaluacion_FyB.pdf - //
weblog.maimonides.edu/farmacia/archives/0216_Admin_FarmEcon.pdf - //
www.proz.com/kudoz/english_to_spanish/art_literary/523942-key_factors.html - 65k - // www.llave.connmed.com.ar/portalnoticias_vernoticia.php?codigonoticia=17715 // www.frusculleda.com.ar/homepage/espanol/activities_teaching.htm // http://www.on24.com.ar/nota.aspx?idNot=36331 ||